Abstract
Background: The Severe Acute Respiratory Syndrome (SARS)–Coronavirus 2 (CoV–2) pandemic pressureon healthcare systems can exhaust ventilator resources. Our objective was a rapid validation of a turbine–based ventilator for invasive as well as non-invasive ventilation.
Methods: Validation comprised (a) testing tidal volume (VT) delivery in 11 simulated models, with various resistances and compliances; (b) comparison with a commercial model (VIVO–50 ventilator, Breas) adapting the UK recommendations for rapidly manufactured ventilators; and (c) in vivo testing in a sheep first with healthy lungs and then with acute respiratory distress syndrome (ARDS) induced by saline lavage.
Results: VT differences in the simulated models were negligible (largest 33 mL [95%–CI 31 to 36]; P<0.001). Pplat was not different (–0.3 cmH2O [95%–CI –0.9 to 0.3]; P=0.409), and PEEP was negligibly different (0.3 cmH2O [95%–CI 0.2 to 0.3]; P<0.001) between the ACUTE–19 and the VIVO–50. Bland–Altman analyses showed good agreement (mean bias, –0.29, [LoA, 0.82 to –1.42], and mean bias 0.56 [LoA, 1.94 to –0.81], at Pplat of 15 and 30 cmH2O, respectively). ACUTE–19 achieved optimal oxygenation and ventilation in healthy and ARDS sheep.
Figure 1. A-D Pplat 15-30 E-L PEEP 5-10-15
Conclusions: The ACUTE–19 performed accurately in simulated and animal models, yielding a comparable performance with a high–quality commercial device.
Footnotes
Cite this article as: European Respiratory Journal 2021; 58: Suppl. 65, PA2432.
This abstract was presented at the 2021 ERS International Congress, in session “Prediction of exacerbations in patients with COPD”.
This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).
- Copyright ©the authors 2021
